Register of Copyrights sides with industry's "market harm" argument for rereleased games.

Dozens of previously hard-to-access games can now be synced via Virtual Machine.

RoboCop: Rogue City revives ‘80s action and satire in an immersive FPS that redefines Alex Murphy’s journey with gritty realism and tactical combat

The 6th edition of the Dehradun Literature Festival held at Doon International School, Curzon Road, had Imtiaz Ali talking about the raison d’etre behind storytelling

Aamir Khan recently kicked off the campaign at New York’s Indian restaurant, The Bungalow, where he was joined by Kiran Rao and hosted by chef Vikas Khanna

Another mobile reveal from Gamescom Opening Night Live 2024 was the latest trailer for the open world dress up game …

Continue reading "Open World Dress Up Game ‘Infinity Nikki’ Gets New Trailer With Closed Beta Sign Ups Now Live, Pre-Registrations Also Available"

Company expects to be cash flow positive in the next two quarters.

Rachelle and Kelly Swan bought their house in Spiritwood two years ago. They gave up their keys to the bank voluntarily in May, closing the door on the bat-infested house.  

Although most of the highest mountains in the world are in Asia (looking at you, Mount Everest and Himalayas), the United States is home to some of the most breathtaking and impressive mountain ranges in the world.

The state’s vote to abolish its high-school exit exam keeps us from knowing how well they’re educating students — which is just how teachers’ unions like it.

If you have an iPhone that can run iOS 18, you can now download and install the public beta of iOS 18.2. One of the most useful new features is the capability to share the location of a lost item connected to Apple's Find My network with a third party. You can already share an item's location with people in your contacts list, but Apple says this could help in instances wherein you have to rely on the help of a stranger.

When you choose "Share Item Location" in the Find My app on iPhone, iPad or Mac, you'll get the option to share a link that shows the location of your missing item. The link's recipient will be able to open it on any device, and they'll also be able to see your Apple account email and/or phone number so that they can get in touch with you. You'll be able to see how many people visited the link, which expires after you're reunited with your lost belonging or after a week if you haven't found it by then.

Along with benevolent strangers, you'll be able to share the locations of misplaced AirTags and Find My accessories with select airlines. Apple has worked with several of them to integrate this feature into their systems. Only a small number of airline staff can access each Share Item Location link, and Apple says they'll first need to authenticate themselves with an Apple Account or partner email address.

Apple

More than 15 airlines will start supporting this feature in the coming months, including Aer Lingus, Air Canada, Air New Zealand, Austrian Airlines, British Airways, Brussels Airlines, Delta Air Lines, Eurowings, Iberia, KLM Royal Dutch Airlines, Lufthansa, Qantas, Singapore Airlines, Swiss International Air Lines, Turkish Airlines, United, Virgin Atlantic and Vueling. Apple says that more airlines will get involved over time to help track down mishandled or delayed bags.

Air transport tech company SITA is also incorporating Share Item Location into WorldTracer, its baggage-tracing system. According to Apple, this is used by more than 500 airlines and ground handlers at more than 2,800 airports.

Of course, installing beta software does have its downsides. There's a higher chance of running into bugs, and some apps or features might still not work as Apple had intended. If you don't mind and want to test iOS 18.2, you'll have to enable Beta Updates under Software Updates in your device's Settings menu. Apple is expected to roll out iOS 18.2 proper in December.

Meanwhile, as luck would have it, there's an early Black Friday deal on AirTags at the time of writing. You can scoop up a four-pack for a record low of $70.

Update, November 5 2024, 9:10AM ET: This story has been updated to clarify that these new features are in the developer beta of iOS 18.2. The public beta for that software isn't available just yet.

Update, November 11, 2024, 3:12PM ET: This story has been updated to include details of the airline integration and to note that a public beta of iOS 18.2 is now available.

This article originally appeared on Engadget at https://www.engadget.com/mobile/apples-latest-find-my-update-makes-it-easier-to-find-lost-items-133049512.html?src=rss

Small businesses say they deliberately avoid earning too much, to stop becoming liable for the sales tax and losing money.

People are really stressed about the U.S. presidential election. A psychiatrist offers several self-help methods to reduce feelings of despair

The U.S. Food and Drug Administration posted a video:

Los medicamentos de receta pasan por muchos pasos y fases importantes antes de que los aprobemos. Las investigaciones, los datos y la evidencia deben demostrar que el medicamento es seguro y eficaz para el uso previsto. Aprenda más sobre el proceso de aprobación de la FDA de principio a fin.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

Quizás sepa que la FDA es responsable de aprobar los medicamentos nuevos, como medicamentos de receta, genéricos, biosimilares y de venta libre, y de garantizar que esos medicamentos sean seguros, de alta calidad y funcionen como se supone que deben hacerlo. Pero nuestro trabajo no termina ahí. Continuamos monitoreando la seguridad y calidad de los medicamentos aprobados en los años venideros. Aprenda más sobre nuestro papel en la regulación de estos medicamentos.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

¿Qué son los biosimilares? Los biosimilares son un tipo de medicamento que se usa para tratar una variedad de afecciones, como enfermedades crónicas de la piel y los intestinos, artritis, diabetes, afecciones renales, degeneración macular y algunos tipos de cáncer. Un biosimilar es un tipo de medicamento biológico. La mayoría de los medicamentos biológicos se elaboran usando fuentes vivas, como células animales, bacterias o levaduras. Debido a que en su mayoría provienen de fuentes vivas, todos los tipos de productos biológicos tienen diferencias menores que ocurren naturalmente entre los lotes de producción. Así como los medicamentos de marca tienen versiones genéricas, los biológicos originales pueden tener biosimilares. La cuidadosa revisión de datos, estudios y pruebas por parte de la FDA ayuda a garantizar que los productos biosimilares brinden los mismos beneficios de tratamiento que el producto biológico original aprobado por la FDA. Los biosimilares pueden brindarle más acceso a tratamientos importantes y también pueden ahorrarle dinero, dependiendo de su cobertura de seguro. Se han aprobado muchos biosimilares diferentes y se esperan aún más. Para obtener más información, visite www.fda.gov/biosimilars

The U.S. Food and Drug Administration posted a video:

La FDA monitorea continuamente datos en tiempo real de pacientes, fabricantes de medicamentos y profesionales de la salud, incluyendo informes de reacciones adversas a los medicamentos de receta. Según estos datos, podemos actualizar las etiquetas de los medicamentos o, en casos excepcionales, solicitar la retirada del mercado. Aprenda más sobre el proceso de la FDA para el monitoreo continuo de los medicamentos aprobados.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

Quizás sepa que la FDA es responsable de aprobar los medicamentos nuevos, como medicamentos de receta, genéricos, biosimilares y de venta libre, y de garantizar que esos medicamentos sean seguros, de alta calidad y funcionen como se supone que deben hacerlo. Pero nuestro trabajo no termina ahí. Continuamos monitoreando la seguridad y calidad de los medicamentos aprobados en los años venideros. Aprenda más sobre nuestro papel en la regulación de estos medicamentos.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The U.S. Food and Drug Administration posted a video:

Los medicamentos de receta pasan por muchos pasos y fases importantes antes de que los aprobemos. Las investigaciones, los datos y la evidencia deben demostrar que el medicamento es seguro y eficaz para el uso previsto. Aprenda más sobre el proceso de aprobación de la FDA de principio a fin.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The U.S. Food and Drug Administration posted a video:

La FDA monitorea continuamente datos en tiempo real de pacientes, fabricantes de medicamentos y profesionales de la salud, incluyendo informes de reacciones adversas a los medicamentos de receta. Según estos datos, podemos actualizar las etiquetas de los medicamentos o, en casos excepcionales, solicitar la retirada del mercado. Aprenda más sobre el proceso de la FDA para el monitoreo continuo de los medicamentos aprobados.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The type 2 diabetes mellitus drug semaglutide is effective for weight loss in non-diabetic overweight or obese adults, when taken alongside a reduced-calorie diet and exercise, researchers have found.

This new 10-minute TEDMED talk is getting quite a bit of attention:


 (if embedded video does not work, try the TED site itself.)

In it, Roger Stein claims to have created an approach to advancing drugs through clinical trials that will "fundamentally change the way research for cancer and lots of other things gets done".

Because the costs of bringing a drug to market are so high, time from discovery to marketing is so long, and the chances of success of any individual drug are so grim, betting on any individual drug is foolish, according to Stein. Instead, risks for a large number of potential assets should be pooled, with the eventual winners paying for the losers.

To do this, Stein proposes what he calls a "megafund" - a large collection of assets (candidate therapies). Through some modeling and simulations, Stein suggests some of the qualities of an ideal megafund: it would need in the neighborhood of $3-15 billion to acquire and manage 80-150 drugs. A fund of this size and with these assets would be able to provide an equity yield of about 12%, which would be "right in the investment sweet spot of pension funds and 401(k) plans".

Here's what I find striking about those numbers: let's compare Stein's Megafund to everyone's favorite Megalosaurus, the old-fashioned Big Pharma dinosaur sometimes known as Pfizer:

	Megafund (Stein)	Megalosaurus (Pfizer)
Funding	$3-15 billion	$9 billion estimated 2013 R&D spend
Assets	80-150	81 (in pipeline, plus many more in preclinical)
Return on Equity	12% (estimated)	9.2% (last 10 years) to 13.2% (last 5)

Since Pfizer's a dinosaur, it can't possibly compete with the sleek, modern Megafund, right? Right?

These numbers look remarkably similar. Pfizer - and a number of its peers - are spending Megafund-sized budget each year to shepherd through a Megafund-sized number of compounds. (Note many of Pfizer's peers have substantially fewer drugs in their published pipelines, but they own many times more compounds - the pipeline is just the drugs what they've elected to file an IND on.)

What am I missing here? I understand that a fund is not a company, and there may be some benefits to decoupling asset management decisions from actual operations, but this won't be a tremendous gain, and would presumably be at least partially offset by increased transaction costs (Megafund has to source, contract, manage, and audit vendors to design and run all its trials, after all, and I don't know why I'd think it could do that any more cheaply than Big Pharma can). And having a giant drug pipeline's go/no go decisions made by "financial engineers" rather than pharma industry folks would seem like a scenario that's only really seen as an upgrade by the financial engineers themselves.
A tweet from V.S. Schulz pointed me to a post on Derek Lowe's In the Pipeline blog. which lead to a link to this paper by Stein and 2 others in Nature Biotechnology from a year and a half ago. The authors spend most of their time differentiating themselves from other structures in the technical, financial details rather than explaining why megafund would work better at finding new drugs. However, they definitely think this is qualitatively different from existing pharma companies, and offer a couple reasons. First,

[D]ebt financing can be structured to be more “patient” than private or public equity by specifying longer maturities; 10- to 20-year maturities are not atypical for corporate bonds. ... Such long horizons contrast sharply with the considerably shorter horizons of venture capitalists, and the even shorter quarterly earnings cycle and intra-daily price fluctuations faced by public companies.

I'm not sure where this line of though is coming from. Certainly all big pharma companies' plans extend decades into the future - there may be quarterly earnings reports to file, but that's a force exerted far more on sales and marketing teams than on drug development. The financing of pharmaceutical development is already extremely long term.

Even in the venture-backed world, Stein and team are wrong if they believe there is pervasive pressure to magically deliver drugs in record time. Investors and biotech management are both keenly aware of the tradeoffs between speed and regulatory success. Even this week's came-from-nowhere Cinderella story, Intercept Pharmaceuticals, was founded with venture money over a decade ago - these "longer maturities" are standard issue in biotech. We aren't making iPhone apps here, guys.

Second,

Although big pharma companies are central to the later stages of drug development and the marketing and distributing of approved drugs, they do not currently play as active a role at the riskier preclinical and early stages of development

Again, I'm unsure why this is supposed to be so. Of Pfizer's 81 pipeline compounds, 55 are in Phase 1 or 2 - a ratio that's pretty heavy on early, risky project, and that's not too different from industry as a whole. Pfizer does not publish data on the number of compounds it currently has undergoing preclinical testing, but there's no clear reason I can think of to assume it's a small number.

So, is Megafund truly a revolutionary idea, or is it basically a mathematical deck-chair-rearrangement for the "efficiencies of scale" behemoths we've already got?

[Image: the world's first known dino, Megalosaurus, via Wikipedia.]

By adopting a contingent workforce model and investing in the right data tools to power better informed decision-making and talent strategy, healthcare organizations can begin to address staffing challenges and turn their talent goals into reality. 

The post Closing Staffing Gaps in Healthcare by Utilizing Diverse Pipelines of Contingent Talent appeared first on MedCity News.

SINGAPORE - When an online retailer began selling his products on e-commerce platform Qoo10 in August 2023, he did not bat an eyelid when it took 30 to 45 days for the platform to disburse his first payout, compared with about three to seven days for other e-commerce sites he was using. But nearly a year later in July, payments owed to his business by Qoo10 had ballooned to about $1.6 million, as the platform’s payment delays exceeded two months and disbursements began trickling in, in smaller amounts. The Singaporean, who wanted to be known only as Mr T and did not wish to divulge what he sold, pulled the plug on his Qoo10 shop this year in the middle of July, and filed a civil claim with the courts. He obtained a default judgment in October for Qoo10 to pay him what he is owed, after the e-commerce site failed to serve a notice of intention to contest or not contest the claim. Mr T, who added that he had borrowed nearly $1 million from banks, friends and relatives to pay his suppliers, said: “I am not holding out hope that I will get much, or any, of my money back from Qoo10... By this point, I just want closure because it’s been so stressful.”

Dec 15, 2023

Mariana Budjeryn writes: War never stops at the border, especially on a continent like Europe. The European Union absorbed millions of Ukrainian war refugees and poured billions of euros into Ukraine's defenses and economic survival. The war permanently reshaped Europe: its demographics, political economy, and energy architecture are shifting in ways that will have irreversible long-term consequences. All of this is because in a very real sense Ukraine already is inextricably woven into the fabric of Europe: Ukraine’s pain is Europe’s pain and Ukraine’s gain will inevitably be Europe's gain, too.

While the BJP-led NDA won resoundingly in the 2019 Lok Sabha election, it has lost power in five major State assemblies since December 2018.

In FY21, national parties and regional parties received ₹427 crore and ₹264 crore worth of funds, respectively, from unknown sources

Kristin Chenoweth teamed up with Allstate to quiz homeowners on the value of the possessions in their home - see what they know, and don't know!

Edmunds.com�s roundup of new vehicles at the 2014 LA Auto Show

Growth Unlocked: Closing the Strategy-to-Execution Gap

Closing Bell Opens Doors for Students

Emerging Chinese Smartphone maker Vargo Technology Showcased in Times Square

Groupe Renault Chairman and CEO Carlos Ghosn today announced plans for a new Alpine sports car and unveiled the Alpine Vision show car.

Plackers presents nutrition and dental health tips to keep kids� teeth clean and mouths healthy.

International Stars at the Closing of the XVIII Habanos Festival

Los artistas m�s grandes llegan a los Premios Billboard de la M�sica Latina �Billboard Duets� que se transmitir� en vivo por TELEMUNDO el jueves 28 de abril a las 8pm/7c

Dale a Papá Regalos Que se Ajusten a su Personalidad

Barbara Bermudo nos habla sobre el regreso al colegio y la importancia de donar leche

Esto es el por que :60

Chairs :60

Máxima y Completa Guía de Regalos Para Las Fiestas

Quéjate fuerte

Conoce al legendario restaurador y mecánico Martín Vaca quien construye autos fuera de serie desde hace más de 50 años. MEXICÁNICOS, estreno el 2 de marzo a las 10PM

Chef Giorgio Rapicavoli de Eating House Miami nos invita participar en el concurso de milk life Somos Fuertes

Los prestigiosos Premios Billboard de la Música Latina tendrán lugar el jueves 30 de abril a las 7pm/6c por Telemundo

Jorge Narvaez habla sobre la unión y la fuerza de la familia

Artistas en los primeros Latin American Music Awards 8 de oct. en TELEMUNDO